Fulgent’s soluble form of paclitaxel has demonstrated significant tumour reduction in various cancer types in Phase I studies. Credit: Lightspring / Shutterstock.com.

Moffitt Cancer Center and Fulgent Pharma have announced a strategic partnership to enhance the development of personalised cancer therapies.

The companies will join forces to progress therapeutics through pre-clinical co-development and clinical development.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The collaboration unites the clinical expertise of Moffitt with Fulgent’s nanotherapeutics and genomics platforms to expedite the creation of targeted cancer treatments.

The agreement grants Fulgent priority access to Moffitt’s clinical capabilities and resources, which will accelerate the progression of Fulgent’s clinical pipeline.

This includes prioritised activation of clinical trials, improved patient screening and efficient data sharing to swiftly deliver investigational therapies to patients.

See Also:

Fulgent Pharma, with expertise in nanoencapsulation technology, developed a soluble form of the chemotherapy drug paclitaxel, named FID-007.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Early Phase I clinical studies have shown significant tumour reduction in breast, head and neck, lung, bile duct, and pancreatic cancers using soluble intravenous FID-007 injection.

The partnership will also focus on co-developing new tailored cancer treatments.

Moffitt will utilise its extensive scientific and immunology knowledge, tissue sample access and nonclinical research resources. Fulgent will provide its nano-particle-based drug development platform and comprehensive genetic and genomic testing capabilities.

Moffitt president and CEO Patrick Hwu stated: “This partnership aligns with Moffitt’s mission to contribute to the prevention and cure of cancer. We are looking forward to working with Fulgent to accelerate the translation of scientific discoveries into lifesaving treatments for our patients.”

In November 2022, Fulgent Pharma was acquired by Fulgent Genetics for $100m.